Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -5.75
- Piotroski Score 3.00
- Grade Sector Perform
- Symbol (ADVM)
- Company Adverum Biotechnologies, Inc.
- Price $7.71
- Changes Percentage (2.25%)
- Change $0.17
- Day Low $7.26
- Day High $7.77
- Year High $29.70
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $28.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$10.20
- Trailing P/E Ratio -0.72
- Forward P/E Ratio -0.72
- P/E Growth -0.72
- Net Income $-117,165,000